Queen's Award Received in 2021 ISO 9001 Certified Delivered over 1,000,000 bio-reagents to life science researchers Trusted by Life Science Communities
Cart summary

You have no items in your shopping cart.

MK-2206

SKU: orb1306994
FeaturedFeatured Product

Description

MK-2206 2HCl is a potent, selective, and orally bioavailable allosteric inhibitor of Akt isoforms (Akt1/2/3). It demonstrates antitumor efficacy in preclinical models and is utilized in cancer research for studying PI3K/Akt signaling in both cellular and animal studies.

Research Area

Cell Biology

Images & Validation

−
MK-2206

Key Properties

−
CAS Number1032350-13-2
MW480.39
Purity>98%
FormulaC25H21N5O·2HCl
SMILESCl.Cl.NC1(CCC1)c1ccc(cc1)-c1nc2ccn3c(n[nH]c3=O)c2cc1-c1ccccc1
TargetKinase
SolubilitySoluble in DMSO ( up to 10 mg/ml with warming)

Bioactivity

−
Target IC50
Akt3:65 nM (cell free)|Akt1:8 nM (cell free)|Akt2:12 nM (cell free)
In Vivo
METHODS: To detect anti-tumor activity in vivo, MK-2206 dihydrochloride (120 mg/kg three times per week or 360 mg/kg once per week, 30% Captisol) and erlotinib (50 mg/kg five times per week, 0.5% methylcellulose + 0.1% Tween 80) were orally administered to CD1 mice bearing human lung cancer tumor NCI-H292 for two weeks. RESULTS: Three-times-weekly MK-2206 monotherapy was ineffective, and the once-weekly regimen mediated only moderate antitumor efficacy. Although erlotinib alone mediated significant tumor growth inhibition, combination therapy with MK-2206 significantly enhanced its antitumor efficacy, including tumor regression. METHODS: To assay antitumor activity in vivo, MK-2206 dihydrochloride (120 mg/kg in 30% captisol) was administered by gavage to NSG mice bearing human endometrial cancer tumors twice a week for three weeks. RESULTS: MK-2206 dihydrochloride treatment resulted in significant inhibition of the growth of three different types and grades of PDX tumors.
Read more...
In Vitro
METHODS: Fourteen tumor cells were treated with MK-2206 dihydrochloride for 72 h. Cell viability was measured by CellTiter-Glo assay. RESULTS: MK-2206 dihydrochloride inhibited the growth of tumor cells with IC50 ranging from 0.1 to 28.6 μmol/L. METHODS: Human nasopharyngeal carcinoma cell lines CNE-2 and HONE-1 were treated with MK-2206 dihydrochloride (0.625-10 μM) for 24-48 h, and the cell cycle was detected by Flow Cytometry. RESULTS: MK-2206 dihydrochloride caused a dose-dependent increase in the percentage of cells in G0/G1 phase and a decrease in the number of cells in S phase.MK-2206 dihydrochloride induced cell cycle arrest in G1 phase. MK-2206 dihydrochloride induces cell cycle arrest in the G1 phase.
Read more...
Cell Research
Cells were seeded at a density of 2 to 3 × 103 per well in 96-well plates. Twenty-four hours after plating, varying concentrations of the drug, either as a single agent or in combination, were added to the wells. Cell proliferation was determined by using the CellTiter-Glo assay at 72 or 96 hours after dosing. The nature of the drug interaction was evaluated by using the combination index (CI) according to the method of Chou and Talalay. A commercial software package was obtained from Calcusyn. In combination with docetaxel, we tested three treatment sequences: (a) MK-2206 followed by docetaxel—cells were exposed to MK-2206 for 24 hours, and then after washout of MK-2206, cells were treated with docetaxel for an additional 72 hours; (b) docetaxel followed by MK-2206—cells were exposed to docetaxel for 24 hours, and then after washout of docetaxel, cells were treated with MK-2206 for an additional 72 hours; and (c) concurrent treatment—cells were exposed to both MK-2206 and docetaxel for 72 hours .
Read more...
Animal Research
When the mean tumor size reached 0.13 cm3 for the SK-OV-3 or 0.2 cm3 for the NCI-H292, HCC70, PC-3, and NCI-H460 models, the mice were randomized into control and treatment groups with approximately equivalent ranges of tumor volume between groups (n = 5 animals per group). The following vehicles were used to dose the compounds: 30% Captisol (Cydex) for MK-2206; 0.5% methylcellulose + 0.1% Tween 80 for erlotinib; distilled water for lapatinib; 0.73% ethanol in saline for docetaxel; and saline for carboplatin and gemcitabine. The control group received vehicle only. Tumor volume was measured with calipers twice a week. Animal body weight and physical signs were monitored during the experiments. Tumor volume was calculated, taking length to be the longest diameter across the tumor and width to be the perpendicular diameter, by using the following formula: (length × width)2 × 0.5. Relative tumor volume was assessed by dividing the tumor volume on different observation days with the starting tumor volume. Statistical significance was evaluated by using the two-way repeated ANOVA test followed by Dunnett's test or an unpaired t-test .
Read more...

Storage & Handling

−
Storage-20°C
Expiration Date12 months from date of receipt.
DisclaimerFor research use only

Alternative Names

−
breast, Akt, Autophagy, Akt2, Akt3, Akt1, Apoptosis, cancer, oral, MK 2206, MK 2206 Dihydrochloride, MK 2206 dihydrochloride, MK2206, MK-2206, MK-2206 (2HCl), MK-2206 2HCl, MK2206 dihydrochloride, MK2206 Dihydrochloride, MK-2206 Dihydrochloride, Inhibitor, inhibit, loss, mutant, PIK3CA, PKB, sensitive, selective, Protein kinase B, PTEN

Similar Products

−
  • MK-2206

    MK-2206 [orb1687434]

    1032349-77-1

    443.94

    C25H22ClN5O

    50 mg, 100 mg, 25 mg
  • MK-2206 free base

    MK-2206 free base [orb1942981]

    1032349-93-1

    407.47

    C25H21N5O

    5 mg, 50 mg
  • MK 2206 dihydrochloride

    MK 2206 dihydrochloride [orb1227109]

    >98% (HPLC)

    1032350-13-2

    480.389

    C25H23Cl2N5O

    2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 200 mg, 1 g, 500 mg, 100 mg
  • 4SC-202 free base

    4SC-202 free base [orb1223678]

    >98% (HPLC)

    910462-43-0

    447.51

    C??H??N?O?S

    1 g, 500 mg, 200 mg, 2 mg, 10 mg, 25 mg, 50 mg, 100 mg, 5 mg
Quality Guarantee

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at [email protected].

Compound Identifiers

PubChem CID
46930998 ↗

Key Properties

−
No computed properties available.

Documents Download

Datasheet
Product Information
Download

Request a Document

Protocol Information

Find More Protocols

MK-2206 (orb1306994)

  • Star
  • Star
  • Star
  • Star
  • Star
  • 0.0
Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

Login to Submit a Review

No reviews yet

Login to review

Step 1: Enter information below

(Recommended: An additional animal making an allowance for loss during the experiment)

Step 2: Enter the in vivo formulation

(This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO +
%+
% Tween 80 +
%

Available Sizes

Select a size below

5 mg
¥ 2,470.00
25 mg
¥ 4,420.00
DispatchUsually dispatched within 3-5 working days
Bulk Enquiry
Need technical support? Find your Distributor Return and Tax Policy

Email

[email protected]

UK Office

+44 (0)1223 859353

US Office

+1 (415) 906-5211

CN Office

+86 (27)-87663101

Distributors

biorbyt.com/distributor